Clinical Trial Update: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with or without SD-101 in hormone-naïve oligometastatic prostate cancer treated with radiotherapy and iADT; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)
• SD-101

Snippet

Sponsor: David Oh | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2025-12-05